TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01203267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin
Description: Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
Study: NCT03562962

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Functional Analytic Psychotherapy
Description: FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle \& Linnerooth, 2000; Kohlenberg \& Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg \& Tsai, 1991).
Study: NCT02960789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formalized clinical assessment of hydration status
Description: Undertake and record a standard formalized clinical hydration assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Take a measurement of body weight on calibrated scales
Description: Standard body weight measurements conducted on calibrated scales

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF wristband hydration status measurement
Description: Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure capillary refill time with manual stopwatch
Description: A standard visual assessment of capillary refill time, aided by the use of a stopwatch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT device hydration status measurement
Description: Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time
Study: NCT02617862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Examination under anaesthetic (EUA)
Description: The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RetCam
Description: The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COSMOS
Description: The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
Study: NCT00910741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoplatin (NC-6004) and Gemcitabine
Study: NCT02578368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 50mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium folinate
Description: can be used to replace leucovorin (calcium folinate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium folinate
Description: can be used to replace leucovorin (calcium folinate)
Study: NCT00211939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium acetate
Description: 667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer
Description: 1-3 tablets t.i.d, titrated to serum phosphorus level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
Study: NCT02578368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
Study: NCT02620163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan/amlodipine 40/5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH22162 40/5/12.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan/amlodipine 80/5mg
Study: NCT01101139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex (single intravenous injection 0.25 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: single intravenous injection Saline 0.9%
Study: NCT00064272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginger extract
Description: Given orally
Study: NCT02622932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and 14C-labeled Anlotinib
Description: oral
Study: NCT04258618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS
Description: Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
Study: NCT03968965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D MvIGS Spine Navigation
Description: The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: 2D Fluoroscopy
Description: Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
Study: NCT03898934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: receive 6000iu daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo for the same period
Study: NCT01939379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.
Study: NCT02549950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peizocorticision
Description: Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Orthodontic Mechanics
Description: Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
Study: NCT04460703

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control message
Description: 2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
Study: NCT02620163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH22162 80/5/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine 40/5mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH22162 40/5/12.5 mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine 80/5mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH22162 80/5/25 mg placebo
Study: NCT00947076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
Study: NCT00211939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
Study: NCT00075374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.~Patients are followed at 1 month and then every 2-3 months thereafter.
Study: NCT04631276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-091
Description: Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-091
Description: Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
Study: NCT01566162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 40-80 mg taken orally taken once daily
Study: NCT00550004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RP101
Description: 190 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine (1000 mg/m2)
Description: 30 minute intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine (1000 mg/m2)
Description: 30 minute intravenous infusion
Study: NCT01551823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine(no Preservative )
Description: Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine(contains Preservative)
Description: Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
Study: NCT03515694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: Injection of 10mL of translucide solution
Study: NCT04173247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraStat Cream
Description: KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Skin Care - Commercially Available Agents
Description: Commercially available skin moisturizers from an approved list that do not interfere with radiation.
Study: NCT04460703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline message
Description: 3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal freedom message
Description: 1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Economic freedom message
Description: 1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-interest message
Description: 1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
Study: NCT04328935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WET
Description: The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
Study: NCT01233622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02605265

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Pelvic Radiation: 50Gy/25Fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pelvic Radiation: 50Gy/25Fx

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT01496443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875 and Glimepiride
Study: NCT04460703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community interest message
Description: 1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
Study: NCT00064272

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02618057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: PO prednisolone, 1 mg/kg/day, for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin, 10mg/kg/day, IV, for 5days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin, 10mg/kg/day, IV, for 5days
Study: NCT04460703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Economic benefit message
Description: 1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guilt message
Description: 1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embarrassment message
Description: 1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anger message
Description: 1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trust in science message
Description: 1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Not bravery message
Description: 1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
Study: NCT05839561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole as monotherapy
Description: Letrozole 5 mg daily orally for 10 days from day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX as monotherapy
Description: MTX in a single dose of 100 mg intravenously on day 0
Study: NCT01439958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation
Description: Twice daily inhalation for a maximum of three years.
Study: NCT02261441

Intervention type: OTHER
Intervention: Observational and noninterventional study
Description: No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
Study: NCT00315302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine 1% once each weekend day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine 1% once each weekend day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plano Lens
Description: Plano lens for the sound eye
Study: NCT00635102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine PO and Glycine IV
Description: Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine PO and Glycine IV
Description: Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo D-Cycloserine PO and placebo Glycine IV
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo D-Cycloserine PO and placebo Glycine IV
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo D-Cycloserine PO and Glycine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo D-Cycloserine PO and Glycine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine PO and placebo Glycine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine PO and placebo Glycine IV
Study: NCT02646475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be used as a placebo comparator.
Study: NCT01183494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI, Avastin, Irinotecan
Description: Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1\*1/\*1 and UGT1A1\*1/\*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI, Avastin, Irinotecan
Description: Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1\*1/\*1 and UGT1A1\*1/\*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
Study: NCT02762058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mirror Therapy
Description: Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Mirror Therapy
Description: Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
Study: NCT02420886

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media
Study: NCT03497689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Description: Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)